Moreover, the inhibition of GSK3β, SIRT1 activity, and proteotoxicity could concomitantly serve as a viable therapeutic approach to enhance NAFLD/NASH treatments. Here, GSK3B is linked to metabolic dysfunction-associated steatotic liver disease.